June 2019 - Volume 3 - Issue - Contributor Index

Author:
J.,
Author:
Jabbour, E.

RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY: PF205

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3:54-55, June 2019.

PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML): PF673

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3:289-290, June 2019.

THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML: S833

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3:370, June 2019.

COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA: PS940

Pullarkat, V. A.; Stock, W.; Lacayo, N. J.; More

HemaSphere. 3:423-424, June 2019.

EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED IN THE INO-VATE TRIAL: OUTCOMES BY SALVAGE-TREATMENT PHASE: PS950

Jabbour, E.; Stelljes, M.; Advani, A. S.; More

HemaSphere. 3:428, June 2019.

EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS): PS1064

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3:481-482, June 2019.

FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP): PS1180

Naqvi, K.; Jabbour, E.; Skinner, J.; More

HemaSphere. 3:537, June 2019.

SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.: S1615

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3:745, June 2019.

IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN: PB1722

Short, N.; Richard-Carpentier, G.; Kanagal-Shamanna, R.; More

HemaSphere. 3:791-792, June 2019.

Author:
Jabeur, D.
Author:
Jablonska, E.

EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA: PF524

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3:214-215, June 2019.

SYK-DEPENDENT P-STAT5 ACTIVITY IS REQUIRED TO MAINTAIN CLONOGENIC POTENTIAL AND OXPHOS METABOLISM IN ACUTE MYELOID LEUKEMIA (AML) CELLS: PS986

Polak, A.; Bialopiotrowicz, E.; Jablonska, E.; More

HemaSphere. 3:443, June 2019.

Author:
Jabr, D.
Author:
Jaccard, A.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL: S103

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3:3, June 2019.

FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA: PF603

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3:255, June 2019.

IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY: PS1377

Roussel, M.; Moreau, P.; Attal, M.; More

HemaSphere. 3:630, June 2019.

POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY: PB2117

Weisel, K.; Dimopoulos, M.; Cook, M.; More

HemaSphere. 3:953, June 2019.

Author:
Jachimowski, L.
Author:
Jack, F.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Jackson, G.

EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK: S873

Pawlyn, C.; Kaiser, M.; Davies, F.; More

HemaSphere. 3:391, June 2019.

Author:
Jackson, H.

THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY: PF558

De Oca, Montes R.; Bhattacharya, S.; Vitali, N.; More

HemaSphere. 3:231, June 2019.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Jackson, J.
Author:
Jacob, F.
Author:
Jacob, J.
Author:
Jacobs, K.
Author:
Jacobs, L.
Author:
Jacobsen, E.

TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY: S869

Witzig, T.; Sokol, L.; Kim, W. S.; More

HemaSphere. 3:389, June 2019.

Author:
Jacobson, A.

COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA: PS940

Pullarkat, V. A.; Stock, W.; Lacayo, N. J.; More

HemaSphere. 3:423-424, June 2019.

Author:
Jacobson, B.
Author:
Jacobson, C. A.

IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE-ARM, MULTICENTER, PHASE 2 TRIAL: PF374

Davids, M. S.; Brander, D. M.; Kim, H. T.; More

HemaSphere. 3:138-139, June 2019.

Author:
Jacomy, D.
Author:
Jacopo, P.

ELDERLY PATIENTS WITH DE NOVO OR SECONDARY AML HAVE COMPARABLE OUTCOMES AFTER INTENSIVE TREATMENTS INCLUDING HIGH DOSE (HD) CYTARABINE AND AUTOLOGOUS (AUTO) OR ALLOGENEIC (ALLO) TRANSPLANTATION (SCT): PS1061

Bernardi, M. S.; Carrabba, M. G.; Pavesi, F.; More

HemaSphere. 3:480, June 2019.

Author:
Jacqmin, H.
Author:
Jacqmin, P.
Author:
Jacques, C.

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR: PF608

Pour, L.; Efebera, Y. A.; Granell, M.; More

HemaSphere. 3:257-258, June 2019.

Author:
Jae, P.

A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION: S1634

Palomba, M. L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3:755, June 2019.

Author:
Jaeger, E.
Author:
Jaeger, U.
Author:
Jaekel, N.
Author:
Jagannath, S.

TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY: PS1384

Jagannath, S.; Narang, M.; Ailawadhi, S.; More

HemaSphere. 3:634, June 2019.

Author:
Jagasia, M.
Author:
Jagdhane, P.
Author:
Jager, A.
Author:
Jäger, E.

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL: PS1331

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3:607-608, June 2019.

Author:
Jäger, R.
Author:
Jäger, U.

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL: PS1331

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3:607-608, June 2019.

Author:
Jaggia, A.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Jaglowski, S.
Author:
Jagurinoski, M.
Author:
Jahn, K.

THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML: S833

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3:370, June 2019.

Author:
Jahn, L.
Author:
Jahn, N.

PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY: PF260

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3:81-82, June 2019.

GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE): PS968

Jahn, N.; Panina, E.; Bullinger, L.; More

HemaSphere. 3:436, June 2019.

MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG): S1616

Rücker, F. G.; Agrawal, M.; Corbacioglu, A.; More

HemaSphere. 3:745-746, June 2019.

Author:
Jahnukainen, K.

DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): PF677

Niemeyer, C. M.; Flotho, C.; Lipka, D. B.; More

HemaSphere. 3:292, June 2019.

Author:
Jahreis, A.

LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL: PF348

Röth, A.; Nagy, Z.; de Latour, Peffault R.; More

HemaSphere. 3:125-126, June 2019.

Author:
Jain, A.

A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL TRIAL OF DAILY VERSUS ALTERNATE DAY ORAL IRON IN TREATMENT OF IRON DEFICIENCY ANEMIA: PF498

Lad, D. P.; Kaundal, R.; Bhatia, P.; More

HemaSphere. 3:201-202, June 2019.

Author:
Jain, G.
Author:
Jain, N.

PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML): PF673

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3:289-290, June 2019.

FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP): PS1180

Naqvi, K.; Jabbour, E.; Skinner, J.; More

HemaSphere. 3:537, June 2019.

Author:
Jain, P.
Author:
Jain, R.

PHASE 1 RESULTS OF ZUMA-4: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PS962

Wayne, A. S.; Huynh, V.; Hijiya, N.; More

HemaSphere. 3:433, June 2019.

Author:
Jain, R. K.

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3: PS945

Shah, B. D.; Bishop, M. R.; Oluwole, O. O.; More

HemaSphere. 3:426, June 2019.

Author:
Jain, S.

IMPACT OF SICKLE CELL DISEASE FROM PATIENTS' AND PHYSICIANS' PERSPECTIVES: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY): PB2300

Osunkwo, I.; Abboud, M.; Andemariam, B.; More

HemaSphere. 3:1026-1027, June 2019.

Author:
Jais, J.-P.

IMPROVEMENTS IN OUTCOME OF MANTLE-CELL LYMPHOMA (MCL) ARE MOSTLY DUE TO ADVANCES IN INDUCTION THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) - A REAL-LIFE NON-INTERVENTIONAL STUDY OF KROHEM: PS1265

Aurer, I.; Misura-Jakobac, K.; Sincic-Petricevic, J.; More

HemaSphere. 3:579, June 2019.

Author:
Jakobsen, L. H.

OSTEOPOROSIS AND LOW-ENERGY FRACTURES AFTER TREATMENT FOR LYMPHOMA WITH CORTICOSTEROID-CONTAINING IMMUNOCHEMOTHERAPY: A DANISH NATIONWIDE COHORT STUDY: PF304

Baech, J.; Hansen, S. M.; Øvlisen, A. K.; More

HemaSphere. 3:104, June 2019.

Author:
Jakubowiak, A.

ELOTUZUMAB IN COMBINATION WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 2 MMRC TRIAL: PS1371

Jasielec, J.; Derman, B.; Major, S.; More

HemaSphere. 3:627, June 2019.

UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PS1375

Costa, L.; Stadtmauer, E.; Davies, F.; More

HemaSphere. 3:629, June 2019.

RELATIONSHIP BETWEEN COMORBIDITY AND ELIGIBILITY CRITERIA FOR CLINICAL TRIALS IN MULTIPLE MYELOMA. A CRITICAL APPRAISAL: PS1404

Persona, Pérez E.; Ormategui, Oiartzabal I.; de Viñaspre, Vega González A.; More

HemaSphere. 3:644-645, June 2019.

Show: